US · Healthcare · Medical Devices
EPS came in at -0.08 against a street estimate of -0.12 — a beat of 33.3%.
Analysts rate MaxCyte Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $4.11.
| Fund | Stake |
|---|---|
| Capricorn Fund Managers Ltd | 7.95% |
| Vitruvian Partners | 4.89% |
| Vanguard Capital Management, LLC | 3.91% |
| Morgan Stanley - Brokerage Accounts | 3.58% |
| Mudita Advisors LLP | 3.27% |
| BlackRock Inc | 2.97% |
| Brooklands Fund Management Limited | 2.76% |
| BNP Paribas Investment Partners SA | 2.69% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MaxCyte Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.